Amarantus BioScience Holdings, Inc. (AMBS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAmarantus BioScience Holdings, Inc. (AMBS) trades at $0.0001. Amarantus BioScience Holdings, Inc. is a biopharmaceutical company focused on developing diagnostic and therapeutic candidates across neurology, psychiatry, ophthalmology, and regenerative medicine. Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for AMBS: AMBS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Amarantus BioScience Holdings, Inc. (AMBS) Healthcare & Pipeline Overview
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company developing diagnostic and therapeutic product candidates in neurology, psychiatry, ophthalmology, and regenerative medicine. Its pipeline includes the LymPro test for Alzheimer's, MSPrecise for multiple sclerosis, Eltoprazine for Parkinson's, and Engineered Skin Substitute for severe burns, supported by strategic research agreements.
What Is the Investment Thesis for AMBS?
Amarantus BioScience Holdings, Inc. presents a research-stage biopharmaceutical profile characterized by a broad pipeline of diagnostic and therapeutic candidates across high-need areas like neurology, oncology, and regenerative medicine. The company's value drivers include the potential for its LymPro test in Alzheimer's diagnostics and MSPrecise for multiple sclerosis, addressing significant unmet needs in early disease detection. The therapeutic candidate Eltoprazine targets Parkinson's disease-related dyskinesia, a condition with limited treatment options. Furthermore, the Engineered Skin Substitute (ESS) is in mid-stage clinical development for severe burns, representing a tangible asset with a clearer path to market compared to earlier-stage assets. Strategic cooperative research and development agreements with institutions like the U.S. Army Institute of Surgical Research and Rutgers University provide external validation and resource leverage for its R&D efforts. However, the company operates with a significantly negative profit margin of -4995.2% and a market capitalization of $0.00B, indicative of a pre-revenue, high-burn-rate development stage typical for early-stage biotechnology firms. The high beta of -12.34 also signals extreme volatility or data anomalies often associated with thinly traded OTC securities. Future value creation is heavily dependent on successful clinical trial outcomes, regulatory approvals, and subsequent commercialization, which are inherently high-risk propositions.
Based on FMP financials and quantitative analysis
AMBS Key Highlights
Market Capitalization stands at $0.00B, indicating a micro-cap or pre-commercial stage enterprise with limited public market valuation.
- Profit Margin is significantly negative at -4995.2%, reflecting substantial operating losses typical for a biopharmaceutical company in the research and development phase with no commercialized products generating revenue.
- Gross Margin is 100.0%, which is characteristic of a company primarily engaged in R&D activities, where direct costs of goods sold are not yet incurred or are negligible relative to overall expenses.
- Beta is reported at -12.34, an exceptionally high negative value suggesting an inverse relationship with market movements, which could be attributed to low trading volume, specific company-centric news, or data anomalies common in thinly traded OTC securities.
- Dividend Yield is None, consistent with a growth-oriented biotechnology company that reinvests all available capital into research and development rather than distributing profits to shareholders.
Who Are AMBS's Competitors?
AMBS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
| QTTB Q32 Bio Inc. | $8.37 | +1.70% | $249M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.26 | +0.97% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AMBS's Key Strengths?
Diverse pipeline of diagnostic and therapeutic candidates addressing multiple high-need medical areas.
- Proprietary diagnostic platforms (LymPro, MSPrecise) and therapeutic candidates (Eltoprazine, ESS).
- Mid-stage clinical development product (ESS) offers a more advanced asset with potential for near-term milestones.
- Strategic cooperative research and development agreements with reputable institutions (U.S. Army, Rutgers University).
What Are AMBS's Weaknesses?
Significantly negative profit margin (-4995.2%) indicates substantial operating losses and high cash burn.
- Market capitalization of $0.00B suggests a very early-stage or distressed valuation, limiting access to capital.
- All products are in development, meaning no current revenue generation and high dependence on future clinical success and regulatory approvals.
- Trading on the OTC market, which typically entails lower liquidity and less stringent disclosure requirements.
What Are the Key Risks for AMBS?
Financial-distress signal — its Altman Z-Score of -19.27 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 5 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High clinical trial failure rates inherent in biopharmaceutical development, particularly for early-stage assets, could prevent any product from reaching commercialization.
- Significant capital requirements and a negative profit margin indicate a continuous need for financing, potentially leading to substantial shareholder dilution through equity raises.
- Intense competition from larger, well-established pharmaceutical and biotechnology companies with greater financial resources and more advanced pipelines could limit market penetration.
- Regulatory hurdles and lengthy approval processes for diagnostic tests and therapeutic drugs pose significant challenges and can delay or prevent market entry.
- The 'Unknown' disclosure status and 'OTC Other' trading tier present risks of limited transparency, low liquidity, and extreme price volatility, making investment highly speculative.
What Are AMBS's Competitive Advantages?
- Proprietary diagnostic technologies such as the LymPro test for Alzheimer's and MSPrecise DNA sequencing assay for multiple sclerosis.
- Exclusive development rights to therapeutic candidates like Eltoprazine for Parkinson's disease-related dyskinesia.
- Advanced cell therapy platform for Engineered Skin Substitute (ESS) in mid-stage clinical development for severe burns.
- Specialized diagnostic and discovery platforms including NuroPro, BC-SeraPro, and PhenoGuard, which can generate future product candidates.
- Cooperative research and development agreements with institutions like the U.S. Army Institute of Surgical Research and Rutgers University, providing access to expertise and resources.
What Does AMBS Do?
Amarantus BioScience Holdings, Inc. is a biopharmaceutical company established in 2008 and headquartered in New York, New York. The company's strategic focus lies in the development of diagnostic and therapeutic product candidates across several critical medical areas, including neurology, psychiatry, ophthalmology, and regenerative medicine. Initially known as Amarantus Bioscience, Inc., the company rebranded to Amarantus BioScience Holdings, Inc. in April 2013, reflecting its evolving corporate structure and broader ambitions within the life sciences sector. Its diagnostic portfolio in development features the lymphocyte proliferation (LymPro) test, a blood-based diagnostic designed for Alzheimer's disease, and MSPrecise, a proprietary DNA sequencing assay aimed at identifying patients with multiple sclerosis. On the therapeutic front, Amarantus is advancing Eltoprazine, a small molecule drug candidate for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders. Another key therapeutic asset is the mesencephalic-astrocyte-derived neurotrophic factor, which is being investigated for its potential in treating various animal models of conditions such as retinitis pigmentosa and retinal artery occlusion. Beyond specific product candidates, the company has also developed several platform technologies, including NuroPro for neurodegenerative disease diagnostics with applications in Parkinson's disease, BC-SeraPro for oncology diagnostics targeting breast cancer, and the PhenoGuard platform for neurotrophic factor discovery. A significant mid-stage clinical development program is the Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product intended for life-threatening severe burns. Amarantus BioScience Holdings, Inc. further strengthens its research and development capabilities through a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University, underscoring its commitment to collaborative innovation in addressing unmet medical needs.
What Products and Services Does AMBS Offer?
- Develop diagnostic blood tests for neurological conditions like Alzheimer's disease (LymPro test).
- Create proprietary DNA sequencing assays for identifying patients with multiple sclerosis (MSPrecise).
- Research and develop small molecule drugs for neurological disorders, such as Eltoprazine for Parkinson's disease Levadopa-Induced Dyskinesia.
- Investigate neurotrophic factors for treating ophthalmological conditions like retinitis pigmentosa and retinal artery occlusion.
- Develop neurodegenerative disease diagnostic platforms (NuroPro) and oncology diagnostic platforms (BC-SeraPro).
- Advance a neurotrophic factor discovery platform (PhenoGuard).
- Develop cell therapy-based autologous skin replacement products for severe burns (Engineered Skin Substitute - ESS).
- Engage in cooperative research and development agreements with academic and governmental institutions.
How Does AMBS Make Money?
- Focuses on research and development of novel diagnostic and therapeutic candidates across multiple disease areas.
- Aims to generate revenue through the eventual commercialization and sales of approved diagnostic tests and pharmaceutical products.
- Potentially seeks licensing agreements or partnerships for its proprietary platforms and drug candidates to fund development and access broader markets.
- Relies on capital raises and strategic agreements to finance its extensive R&D pipeline, given its pre-revenue stage.
- Builds intellectual property through patents on its diagnostic assays, drug compounds, and cell therapies.
What Industry Does AMBS Operate In?
Amarantus BioScience Holdings, Inc. operates within the dynamic and highly specialized Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development, long product development cycles, and significant regulatory hurdles. Key market trends include increasing demand for precision diagnostics, novel therapies for neurodegenerative diseases, and advancements in regenerative medicine. Amarantus's focus on diagnostics for Alzheimer's and multiple sclerosis positions it within a growing segment addressing early detection and personalized medicine. Its therapeutic pipeline, including Eltoprazine for Parkinson's and ESS for severe burns, targets areas with substantial unmet medical needs and large potential market sizes. The competitive landscape is intense, with numerous established pharmaceutical giants and emerging biotech firms vying for market share. Success in this industry is heavily reliant on intellectual property, clinical trial outcomes, and strategic partnerships. Amarantus's cooperative research agreements provide a competitive edge in resource utilization and scientific validation, but it faces competition from companies with more advanced pipelines and greater financial resources.
Who Are AMBS's Key Customers?
- Healthcare providers and clinicians seeking advanced diagnostic tools for neurological and psychiatric conditions.
- Patients suffering from neurodegenerative diseases like Alzheimer's and Parkinson's, and autoimmune diseases like multiple sclerosis.
- Hospitals and burn centers requiring advanced regenerative medicine solutions for severe burn treatment.
- Pharmaceutical companies potentially interested in licensing or acquiring Amarantus's drug candidates or diagnostic platforms.
- Research institutions and academic partners collaborating on scientific discovery and product development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Amarantus BioScience Holdings, Inc. stands at 21.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -46.7%, showing how much profit it generates from its asset base. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Amarantus BioScience Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, United States.
Financial Health
Amarantus BioScience Holdings, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.27 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Amarantus BioScience Holdings, Inc. has missed Wall Street's EPS estimate in 4 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 186.3% below estimates on average.
Insider Activity
12 transactions · 8 purchases, 0 sales, 4 other transactions · 4 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
AMBS Financials
AMBS Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
AMBS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AMBS.
Price Targets
Wall Street price target analysis for AMBS.
AMBS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AMBS; grades run from A+ (80-100) to F (below 30).
AMBS OTC Market Information
Amarantus BioScience Holdings, Inc. trades on the 'OTC Other' tier of the OTC market. This tier typically includes companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, or those that are not required to report to the SEC. Companies in the 'OTC Other' category often have limited public information, may be in early development stages, or could be distressed. This classification generally implies higher risk due to less transparency and potentially less stringent reporting requirements compared to companies listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited Disclosure: The 'Unknown' disclosure status on the OTC market means investors may have access to very limited or infrequent financial and operational information, making informed decision-making challenging.
- Low Liquidity: Trading on the 'OTC Other' tier and a $0.00B market cap typically results in extremely low trading volume, leading to wide bid-ask spreads and difficulty in buying or selling shares without significantly impacting the price.
- Price Volatility: Shares traded on OTC markets, especially those with low liquidity, are often subject to extreme price fluctuations due to limited market depth and susceptibility to speculative trading.
- Lack of Analyst Coverage: Companies on the 'OTC Other' tier rarely receive coverage from institutional analysts, leaving investors without independent research and valuation insights.
- Risk of Delisting/Cessation of Trading: Companies that fail to meet even minimal reporting or operational standards on the OTC market face the risk of having their shares delisted or ceasing to trade entirely.
- Verify the company's current financial statements and operational reports, if any are publicly available, to assess its cash position and burn rate.
- Investigate the status and progress of each product candidate in the pipeline, including clinical trial phases and regulatory timelines.
- Research the background and track record of management, beyond what is publicly stated, to understand their experience and credibility.
- Examine any intellectual property filings, such as patents, to understand the defensibility of its technologies.
- Assess the competitive landscape for each of its product areas to understand market potential and competitive threats.
- Review the company's capital structure, including outstanding shares, warrants, and convertible debt, to understand potential dilution.
- Evaluate any recent news or press releases for updates on partnerships, funding, or clinical milestones.
- Specific and detailed product pipeline across multiple therapeutic and diagnostic areas, indicating active R&D.
- Cooperative research and development agreements with reputable institutions like the U.S. Army Institute of Surgical Research and Rutgers University.
- Headquartered in a major financial and biotech hub (New York City), suggesting a professional operational base.
- Clear historical evolution from Amarantus Bioscience, Inc. to Amarantus BioScience Holdings, Inc. in 2013, indicating corporate development.
- Focus on high-impact disease areas such as Alzheimer's, Parkinson's, multiple sclerosis, and severe burns, addressing significant unmet medical needs.
What Investors Ask About Amarantus BioScience Holdings, Inc. (AMBS) — Healthcare
What are the main risks for AMBS?
Investing in Amarantus BioScience Holdings, Inc. carries several significant risks, primarily stemming from its nature as a pre-revenue, R&D-stage biopharmaceutical company. A major risk is the high failure rate associated with clinical trials; any of its product candidates could fail to demonstrate efficacy or safety, leading to substantial losses.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Word count for CEO Profile background and track record fields could not be met due to lack of specific information in source data, adhering to 'ONLY use facts from the provided source data' and 'If a fact is not in sources, output 'Unknown'' rules.